Drug Profile


Alternative Names: Dexilant; Dexivant; Kapidex™; T-168390; TAK-390; TAK-390 modified release; TAK-390MR; TAK-390MROD

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • No development reported Gastrointestinal disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In children, In infants) in USA (PO, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-disorders(In volunteers) in USA (PO, Fast dissolve)
  • 26 Oct 2017 Takeda plans a phase I pharmacokinetics trial of dexlansoprazole 30 mg and 60 mg delayed-release capsules in China (In volunteers) in 2017 (NCT03316976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top